albuterol / budesonide vs fluticasone propionate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

albuterol / budesonide · Airsupra

Marketed by AstraZeneca

Approved in Asthmacombination (SABA + ICS)
Reliable signal

NCT03769090 · Phase 3 · completed

Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).

Next expected readout: February 2027 · NCT06422689 (registry estimate)

Reported efficacy

Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 (met)

Result source: NCT05505734

fluticasone propionate

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT07664527 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol /​ budesonidefluticasone propionate
Severe exacerbations, annualised rate0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
1 other result
  • 2.6 vs 2.7 250/50 mcg BID · wk 52 · n 310 · Phase 4 · secondary NCT00452348
Trough FEV1, change0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
0.2 vs 0.1+0.2 vs placebo100 mcg · wk 12 · n 129NCT02139644
25 other results
  • 0.2 vs 0.1 50 mcg · wk 12 · n 128 · Phase 3 · primary NCT02139644
  • 0.1 vs 0.0 200 mcg · wk 26 · n 120 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · primary NCT01576718
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · primary NCT01576718
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · secondary NCT01576718
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · secondary NCT01576718
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767
ACQ-5, change—Not posted · NCT06502366—Not posted · NCT00158834
OCS dose reduction—Not posted · NCT06502366—Not posted · NCT00158834

Severe exacerbations, annualised rate

albuterol /​ budesonide
0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
fluticasone propionate
1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
1 other result
  • 2.6 vs 2.7 250/50 mcg BID · wk 52 · n 310 · Phase 4 · secondary NCT00452348

Trough FEV1, change

albuterol /​ budesonide
0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
fluticasone propionate
0.2 vs 0.1+0.2 vs placebo100 mcg · wk 12 · n 129NCT02139644
25 other results
  • 0.2 vs 0.1 50 mcg · wk 12 · n 128 · Phase 3 · primary NCT02139644
  • 0.1 vs 0.0 200 mcg · wk 26 · n 120 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · primary NCT01576718
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · primary NCT01576718
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · secondary NCT01576718
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · secondary NCT01576718
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767

ACQ-5, change

albuterol /​ budesonide
—Not posted · NCT06502366
fluticasone propionate
—Not posted · NCT00158834

OCS dose reduction

albuterol /​ budesonide
—Not posted · NCT06502366
fluticasone propionate
—Not posted · NCT00158834
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. albuterol / budesonide: 5 of 5 rows · fluticasone propionate: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricalbuterol /​ budesonide
Rows use multiple source trials
fluticasone propionate
Rows use multiple source trials
FEV1 Max Fall
absolute value · percentage points
5.45% (n=60) vs 18.97% (n=59) placeboa,b,c,d
NCT04234464 · Phase 3 · registry result, not featured evidence
-9.5% (n=113) vs -12.7% (n=104) FP @ 4wk100/50mcg BIDa,b,c,d
NCT00118716 · Phase 4 · registry result, not featured evidence
Dropout rate
9.9%160/180 μge
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
11.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
28.2%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
3.6%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
7.8%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
—100/25 µg QDf
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
53.1%Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
37.5%Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
26.5%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
25.5%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
2.8%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
28%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
27.5%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
20.3%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
21.1%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.4%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.4%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.7%160/180 μge
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
0.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
0.5%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0.5%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
—100/25 µg QDf
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
—Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
3.3%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
1.9%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
—50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
1.7%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.8%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.9%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Serious AEs
5.2%160/180 μge
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
3.8%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
3.1%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
2%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0%160/180
NCT06245551 · Phase 3
0%
NCT05555290 · Phase 3 · registry result, not featured evidence
0%
NCT04234464 · Phase 3 · registry result, not featured evidence
0%160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
1.4%100/25 µg QDf
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
0%50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
0%Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
4.6%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
2.3%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
2%50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
0%100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
1.9%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0.8%100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
0%50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
9.8%200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
6.4%200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5%100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5.5%100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
0.6%100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
0.8%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.8%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
—25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0.9%100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0.9%50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0%400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
1.9%100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
1%50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
160/180 μge
nasopharyngitis 7.5%
headache 4.3%
covid-19 3.3%
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
80/180 μg
nasopharyngitis 5.8%
headache 4.7%
covid-19 4.5%
NCT03769090 · Phase 3 · Asthma · phase 3
160/180 μg
upper respiratory tract infection 5.4%
covid-19 5.1%
nasopharyngitis 3.7%
NCT05505734 · Phase 3 · Asthma · phase 3
160/180 μg
nasopharyngitis 7.6% (placebo 5.5%)
headache 5.1% (placebo 7%)
dysphonia 2% (placebo 0%)
NCT03847896 · Phase 3 · Asthma · phase 3
80/180 μg
nasopharyngitis 6.4% (placebo 5.5%)
headache 4.9% (placebo 7%)
upper respiratory tract infection 1.5% (placebo 1%)
NCT03847896 · Phase 3 · Asthma · phase 3
160/180
bronchial irritation 1.6% (placebo 0%)
diarrhoea 0% (placebo 1.6%)
headache 0% (placebo 1.6%)
NCT06245551 · Phase 3
anxiety 1%
cough 1%
covid-19 1%
NCT05555290 · Phase 3 · registry result, not featured evidence
anxiety 0% (placebo 1.7%)
dyspnoea 0% (placebo 1.7%)
NCT04234464 · Phase 3 · registry result, not featured evidence
160/180 μg
miliaria 0%
NCT04848662 · Phase 1 · registry result, not featured evidence
100/25 µg QDf
upper respiratory tract infection 6.8%
NCT02730351 · Phase 4 · registry result, not featured evidence
show 29 more results
250/50 mcg BID
upper respiratory tract infection 20.3%
headache 18.3%
nasopharyngitis 17.6%
NCT00452699 · Phase 4 · registry result, not featured evidence
250/50 mcg BID
nasopharyngitis 17.4%
headache 16.5%
upper respiratory tract infection 14.5%
NCT00452348 · Phase 4 · registry result, not featured evidence
50/100 mcg BD
headache 18%
nasopharyngitis 9.3%
rhinitis 8%
NCT00353873 · Phase 4 · registry result, not featured evidence
100/50mcg BID
headache 3.2%
upper respiratory tract infection 3.2%
abdominal pain upper 2.4%
NCT00118716 · Phase 4 · registry result, not featured evidence
50/12.5 mcg BID
nasopharyngitis 4.3% (placebo 5.3%)
NCT02980133 · Phase 3 · registry result, not featured evidence
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
100 mcg
headache 7% (placebo 3.9%)
nasopharyngitis 7% (placebo 3.1%)
upper respiratory tract infection 3.1% (placebo 4.7%)
NCT02139644 · Phase 3 · registry result, not featured evidence
50 mcg
nasopharyngitis 5.4% (placebo 3.1%)
upper respiratory tract infection 5.4% (placebo 4.7%)
headache 1.6% (placebo 3.9%)
NCT02139644 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
200/12.5 mcg
upper respiratory tract infection 18%
sinusitis 10.5%
nasopharyngitis 9%
NCT02175771 · Phase 3 · registry result, not featured evidence
200 mcg
upper respiratory tract infection 13.6%
cough 10.4%
nasopharyngitis 10.4%
NCT02175771 · Phase 3 · registry result, not featured evidence
100/12.5 mcg
upper respiratory tract infection 17.5%
nasopharyngitis 12.5%
cough 11.7%
NCT02175771 · Phase 3 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 18.1%
nasopharyngitis 13.4%
sinusitis 11.8%
NCT02175771 · Phase 3 · registry result, not featured evidence
100/50 HFA
headache 15%
nasopharyngitis 9.2%
upper respiratory tract infection 6.4%
NCT00441441 · Phase 3 · registry result, not featured evidence
100 µg OD
cough 8.5% (placebo 5%)
headache 5.9% (placebo 1.7%)
rhinorrhoea 5.1% (placebo 1.7%)
NCT01563029 · Phase 2 · registry result, not featured evidence
50 µg OD
pharyngitis 5.8% (placebo 3.4%)
bronchitis 3.3% (placebo 0.8%)
nasopharyngitis 3.3% (placebo 3.4%)
NCT01563029 · Phase 2 · registry result, not featured evidence
25 µg OD
nasopharyngitis 7.6% (placebo 3.4%)
cough 5.9% (placebo 5%)
oropharyngeal pain 5.1% (placebo 0.8%)
NCT01563029 · Phase 2 · registry result, not featured evidence
12.5 OD
nasopharyngitis 8.8% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
25 OD
nasopharyngitis 7.9% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
6.25 OD
nasopharyngitis 7% (placebo 7%)
headache 5.3% (placebo 3.5%)
influenza 3.5% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
200 mcg
headache 4.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
100 mcg
headache 3.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
50 mcg
headache 4.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
400 mcg
headache 6.5% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 4.9% (placebo 2.9%)
nasopharyngitis 2.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence
50 mcg
nasopharyngitis 6.7% (placebo 4.8%)
upper respiratory tract infection 2.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
25 mcg
nasopharyngitis 4.8% (placebo 4.8%)
upper respiratory tract infection 1.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
12.5 mcg
upper respiratory tract infection 6.8% (placebo 2.9%)
nasopharyngitis 3.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation comparability has not been reviewed for 4 of these studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

albuterol / budesonide

Severe Exacerbation 22.9% (n=1054) vs 26.2% (n=1014) AS MDI80/180 μg
event rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 241 Participants as posted
ACQ-5 64.7% (n=1052) vs 62.1% (n=1014) AS MDI @ 24wk80/180 μg
responder rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 681 Participants as posted
Time to First Severe Exacerbation 5.1% (n=1209) vs 9.1% (n=1212) PT007160/180 μg
event count · % of participants
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 62 Participants as posted
show 3 more results
5.3% (n=1209) vs 9.4% (n=1212) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 64 Participants as posted
6% (n=1180) vs 10.7% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 71 Participants as posted
6.2% (n=1180) vs 11.2% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 73 Participants as posted
Total Systemic Glucocorticoid Exposure mg Per 23.2 vs 61.9 PT007 per year160/180 μg
absolute value · per year
NCT05505734 · Phase 3 · Asthma · phase 3
show 1 more result
23 vs 63 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
Total Systemic Glucocorticoid Duration 0.01 vs 0.03 PT007 months160/180 μg
absolute value · months
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
show 1 more result
0.01 vs 0.03 PT007 months*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
FEV1 AUC0-6 0.259 vs 0.097 placebo L @ 12wk160/180 μg
absolute change · L
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 258.6 mL as posted
show 1 more result
0.242 vs 0.097 placebo L @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 242.2 mL as posted
Time to FEV1 15 Increase 7.5 vs 14 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
7 vs 14 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
Duration of FEV1 15 Increase 185.5 vs 229.5 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
174 vs 229.5 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
ACQ-7 66.5% (n=161) vs 55.3% (n=159) placebo @ 12wk160/180 μg
responder rate · % of participants
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 107 Participants as posted
show 1 more result
65.5% (n=165) vs 55.3% (n=159) placebo @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 108 Participants as posted
FEV1 Max Fall 6.95% (n=64) vs 24.46% (n=64) placebo160/180
absolute value · percentage points
All subjects
NCT06245551 · Phase 3
FEV1 Max Fall LT 10 75% (n=64) vs 3.1% (n=64) placebo160/180
event count · % of participants
Maximum percentage fall <10%
NCT06245551 · Phase 3 · converted to % from 48 Participants as posted
FEV1 AUC0-30min -0.1 vs -0.44 placebo L160/180
absolute value · L
NCT06245551 · Phase 3

+ 10 further endpoints in the CSV export.

fluticasone propionate

Max Post-exercise FEV1 Fall 15.02% (n=70) vs 16.71% (n=69) FP @ 2wk100/25 µg QD
percent change · % of baseline
NCT02730351 · Phase 4 · registry result, not featured evidence
show 1 more result
11.9% (n=68) vs 14.05% (n=69) FP @ 2wk100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
FEV1 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Daily
absolute change · L
NCT02301975 · Phase 3 · registry result, not featured evidence
show 2 more results
0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
AM PEF Change L/Min 23.6 vs 9.8 Fluticasone Propionate L @ 52wk250/50 mcg BID
absolute change · L
NCT00452699 · Phase 4 · registry result, not featured evidence
Asthma Symptom Free 27.3 vs 28.6 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence
show 1 more result
37.1 vs 28.5 Fluticasone Propionate % of time @ 52wk250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
Morning PEF 10.03 vs 2.24 placebo L @ 12wk200 mcg
absolute change · L
NCT01576718 · Phase 2 · registry result, not featured evidence
show 12 more results
10.29 vs 2.52 placebo L @ 12wk200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
16.3 vs 9.1 FP L @ 4wk100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
14.517 vs 3.591 placebo L @ 12wk100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
9.34 vs 2.24 placebo L @ 12wk100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
9.39 vs 2.52 placebo L @ 12wk100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
32 vs 12.3 placebo L @ 12wk50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
10.609 vs 3.591 placebo L @ 12wk50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
10.48 vs 2.24 placebo L @ 12wk50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
10.85 vs 2.52 placebo L @ 12wk50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
9.61 vs 2.24 placebo L @ 12wk400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
10.4 vs 2.52 placebo L @ 12wk400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
27.7 vs 14.6 FP DISKUS L @ 52wk250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
Asthma Symptom-Free 37.4 vs 28.9 FP DISKUS % of time @ 52wk250/50 mcg BID
percent change · % of time
NCT00452348 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 26.9 vs 19.3 FP L @ 12wk50/100 mcg BD
absolute change · L
NCT00353873 · Phase 4 · registry result, not featured evidence
show 4 more results
27.55 vs 9.26 placebo L @ 12wk100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
29.58 vs 9.26 placebo L @ 12wk50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
21.01 vs 9.26 placebo L @ 12wk25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
30.99 vs 9.26 placebo L @ 12wk12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Morning PEF Change L/Min 27.7 vs 18.4 FP L/min @ 12wk50/100 mcg BD
absolute change · L/min
NCT00353873 · Phase 4 · registry result, not featured evidence
show 6 more results
13.7 vs 6.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
14.4 vs 7.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.9 vs 6.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
17 vs 7.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12 vs 6.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.3 vs 7.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Well-Controlled Asthma 43.3% (n=150) vs 40.1% (n=152) FP50/100 mcg BD
event count · % of participants
NCT00353873 · Phase 4 · registry result, not featured evidence · converted to % from 65 Participants as posted
FEV1 AUC0-4h 0.7 vs 0.3 FP L @ 0wk100/50mcg BID
absolute change · L
NCT00118716 · Phase 4 · registry result, not featured evidence
Evening PEF 10.8 vs 7.6 FP L/min @ 4wk100/50mcg BID
absolute change · L/min
NCT00118716 · Phase 4 · registry result, not featured evidence
show 6 more results
13.5 vs 5.1 placebo L/min @ 12wk100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
11 vs 5 placebo L/min @ 12wk100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
18.5 vs 5.1 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
18.2 vs 5 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
16.3 vs 5.1 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
16.2 vs 5 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
Rescue-free 59.4 vs 54.7 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence

+ 29 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · fluticasone propionate's landscape